Researchers identify important neural mechanism responsible for certain...
Pain typically has a clear cause-but not always. When a person touches something hot or bumps into a sharp object, it's no surprise that it hurts. But for people with certain chronic pain disorders,...
View ArticleNovartis announces FDA approval of Signifor LAR for treatment of patients...
Novartis announced today that the US Food and Drug Administration has approved Signifor long-acting release (LAR) (pasireotide) for injectable suspension, for intramuscular use, for the treatment of...
View ArticleNovel technique could help identify cancerous tissue during brain tumor surgery
A novel radioguided surgery technique could quickly and effectively identify residual cancer cells during brain tumor surgery, with low radiation exposure for both patients and surgeons. The study,...
View ArticleIpsen's Somatuline Depot Injection 120 mg receives FDA approval for treatment...
Ipsen Biopharmaceuticals, Inc., an affiliate of Ipsen, today announced that Somatuline Depot (lanreotide) Injection 120 mg (referred to as Somatuline) was approved by the U.S. Food and Drug...
View ArticleChiasma announces publication of octreotide capsules Phase III study results...
Chiasma Inc., a U.S. privately-held biopharma company, announced today that results from a multicenter Phase III study of the investigational new drug, octreotide capsules, were published online for...
View ArticleCarnegie Mellon study identifies intermediary neuron system that acts as...
Neuroscientists believe that the connectome, a map of each and every connection between the millions of neurons in the brain, will provide a blueprint that will allow them to link brain anatomy to...
View ArticleChiasma closes $70 million Series E financing round
Chiasma, Inc., a U.S. privately-held biopharma company developing octreotide capsules, its lead product for the orphan condition acromegaly, today announced the closing of a $70 million Series E...
View ArticleUnderstanding crosstalk between cells in the pancreas can help treat diabetes
Sometimes, listening in on a conversation can tell you a lot. For Mark Huising, an assistant professor in the Department of Neurobiology, Physiology and Behavior at the UC Davis College of Biological...
View ArticleFDA accepts Chiasma's NDA filing for octreotide capsules for treatment of...
Chiasma, Inc., a U.S. late-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration has accepted for filing the Company's New Drug Application (NDA) for the marketing...
View ArticleEverolimus, 177Lu-dotatate extend neuroendocrine tumour PFS
Positive progression-free survival results from the RADIANT-4 and NETTER-1 trials extend the armamentarium for physicians treating patients with neuroendocrine tumours.
View ArticleResearchers find how different neurons work together to reduce responses to...
Being able to understand speech is essential to our evolution as humans. Hearing lets us perceive the same word even when spoken at different speeds or pitches, and also gives us extra sensitivity to...
View ArticleLexicon's telotristat etiprate improves social and physical function,...
Lexicon Pharmaceuticals, Inc.'s telotristat etiprate, the first oral therapy in development for the treatment of carcinoid syndrome (CS), was associated with patient-reported improvements in social and...
View ArticleStudy demonstrates efficacy of everolimus in treating nonfunctional...
The results of the international, multicenter, Phase 3 RADIANT-4 study clearly demonstrate the efficacy of the agent everolimus in treating nonfunctional neuroendocrine tumours of lung or...
View ArticleLexicon announces top-line results from TELECAST Phase 3 study of telotristat...
Lexicon Pharmaceuticals, Inc. announced today that top-line data from its TELECAST Phase 3 study showed results of telotristat etiprate in treating carcinoid syndrome in cancer patients with metastatic...
View ArticleNovartis announces FDA approval of Afinitor for progressive, nonfunctional...
Novartis today announced that the United States Food and Drug Administration approved Afinitor (everolimus) tablets for the treatment of adult patients with progressive, well-differentiated,...
View ArticleAltered circadian somatostatin expression linked to bipolar disorder
Results of the first study of its kind to link abnormalities in circadian rhythms to changes in specific neurotransmitters in people with bipolar disorder will be published this week in the journal...
View ArticleAdvanced imaging kit Netspot gets FDA approval to detect rare neuroendocrine...
The U.S. Food and Drug Administration today approved Netspot, the first kit for the preparation of gallium Ga 68 dotatate injection, a radioactive diagnostic agent for positron emission tomography...
View ArticleClinical study shows improved outcomes for NET patients treated with...
NETTER-1 study, showing clinically meaningful and significant results for Lutathera (77Lu-DOTA0-Tyr3-Octreotate) in patients with metastatic midgut neuroendocrine tumors (NETs). The data will be...
View ArticleGenetic blood test can help predict patient’s respone to neuroendocrine...
Malignant neuroendocrine tumors (NETs) are relatively rare, notoriously difficult to treat, and associated with poor long-term survival. According to research presented at the 2016 Annual Meeting of...
View ArticleMolecular imaging technique could help optimize radiotherapy dose to combat NETs
Aggressive neuroendocrine cancer is something of a dark horse--a rare, elusive and persevering force linked to discouraging long-term survival rates.
View Article